Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need. Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...
Well, great. Thank you, everybody, for being seated. Welcome. I'm Roger Jeffs, CEO of Liquidia, and welcome to our first ever R&D Day. We're really excited about what we're able to share with you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results